Abstract Library

#3006 Teratoma with Malignant Transformation: A Case Report of a Neuroendocrine Tumor That Arises from the Bronchial Mucosa in a Mature Cystic Teratoma

Introduction: Mature cystic teratoma (MCT) is the most common type of germ cell tumor in the ovary. A malignant tumor that arises in a pre-existing mature teratoma is called teratoma with malignant transformation (TMT).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Espinola Benza M

Authors: Espinola Benza M, La Salvia A, Hernandez Sanchez L, Gallardo Gallego R, Suarez Pita D,

Keywords: Mature cystic teratoma, teratoma with malignant transformation, surgical resection,

#2801 IMMUNeOCT: OCT LAR in the Induction of Immunologic Response in Patients with Neuroendocrine Neoplasms (NENs): A Perspective Observational and Translational Study (EudraCT2017-001613-83)

Introduction: The possible impact of octreotide (OCT) Long-Acting Release (LAR) on the immune system regulation is largely unexplored.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ottaiano A, Rea G, Capozzi M, Napolitano M, Tatangelo F,

Keywords: Octreotide, Tregs, MDSCs, immune system,

#1215 Describing NENs: Just Clinical/Biologic Features or Actual Prognostic Factors?

Introduction: Neuroendocrine neoplasias (NENs) are a rare group of diseases, with several possible locations and manifestations, often representing a challenging diagnosis. It is essential to improve tools that accurately predict aggressiveness and prognosis.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Ribeiro C

Authors: Ribeiro C, Gomes F, Semedo M, Filipe F, Oliveira S,

Keywords: Neuroendocrine neoplasias, prognosis,

#993 Analysis of Somatostatin Receptors Expression in Neuroendocrine Tumors

Introduction: Clinical studies have suggested anti-tumor efficacy of somatostatin analog (SSA) in the treatment of neuroendocrine tumors (NETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Li T

Authors: Li T, Qian Z, Ter-Minassian M, Chan J, Brais L,

Keywords: SSTR2, SSA, NET, OS, PFS,

#869 Phase 1 Expansion Study of an Oral TORC1/TORC2 Kinase Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET)

Introduction: Clinical efficacy of everolimus, an allosteric TORC1-selective inhibitor, has been established in pancreatic NET. CC-223 is an ATP-competitive inhibitor of the mTOR kinase, inhibiting both TORC1 and TORC2.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Meyer T, Mahipal A, Bendell J, Nemunaitis J, Mita M,

Keywords: TORC-1 CC-223,